Comparative clinical trial with a new substance, Diftalone, versus indomethacin in 30 patients affected with rheumatoid arthritis.
During a double-blind, randomized study on 30 patients affected with classic or definite rheumatoid arthritis, the efficacy and safety of treatment with diftalone in a per oral dosage of 500 mg/day were compared with those of indomethacin given orally at doses of 50-75 mg/day initially and 100 mg/day subsequently, for a treatment period of 24 months. In this long-term study, diftalone demonstrated that its effectiveness and safety in the treatment of rheumatoid arthritis are clearly comparable to those of indomethacin.
D000284:Administration, Oral; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D011724:Pyridazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D011724:Pyridazines; D007213:Indomethacin